Novavax (NVAX) Misses Q3 EPS, Revenue Beats; Guides to Low End
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $10.19 -0.29%
Financial Fact:
Research and development: 52.98M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Financial Fact:
Research and development: 52.98M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q3 EPS of ($2.15), $3.78 worse than the analyst estimate of $1.63. Revenue for the quarter came in at $735 million versus the consensus estimate of $623.9 million.
GUIDANCE:
Novavax sees FY2022 revenue of $2 billion, versus the consensus of $2.04 billion.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- BMO Capital Starts Lululemon (LULU) at Underperform
- Chime to acquire Stride Bank for $590M in cash
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
